603676.SH
卫信康
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 9.14
−2.04%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.2B | 1.1B | 1.3B | 1.3B | 1.4B |
| Cost of Revenue | 447.3M | 437.8M | 594.9M | 650.5M | 662.9M |
| Gross Profit | 714.8M | 697.9M | 705.3M | 672.1M | 735.7M |
| Operating Expenses | |||||
| R&D Expense | 107.3M | 110.6M | 116.0M | 112.8M | 72.5M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 129.7M | 130.4M | 136.9M | 148.4M | 171.8M |
| Selling & Marketing Expense | 246.3M | 226.0M | 210.5M | 255.4M | 312.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 495.4M | 478.0M | 474.0M | 526.4M | 568.7M |
| Cost and Expenses | 942.7M | 915.8M | 1.1B | 1.2B | 1.2B |
| Operating Income (EBIT) | 277.3M | 291.6M | 280.9M | 175.0M | 162.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 269.6M | 283.6M | 276.6M | 215.8M | 182.4M |
| Income Tax Expense | 52.9M | 50.7M | 30.4M | 1.8M | 5.4M |
| Bottom Line | |||||
| Net Income | 216.7M | 232.9M | 246.2M | 214.0M | 177.0M |
| Earnings from Cont. Ops | 216.7M | 232.9M | 246.2M | 214.0M | 177.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 216.7M | 232.9M | 246.2M | 214.0M | 177.0M |
| Per Share | |||||
| Basic EPS | CN¥0.50 | CN¥0.54 | CN¥0.57 | CN¥0.50 | CN¥0.41 |
| Diluted EPS | CN¥0.50 | CN¥0.54 | CN¥0.57 | CN¥0.50 | CN¥0.41 |
| Revenue Per Share | CN¥2.72 | CN¥2.63 | CN¥3.01 | CN¥3.09 | CN¥3.24 |
| Shares | |||||
| Basic Shares Outstanding | 427.1M | 431.2M | 431.9M | 428.0M | 431.6M |
| Diluted Shares Outstanding | 427.1M | 431.2M | 431.9M | 428.0M | 431.6M |
| Profitability Metrics | |||||
| EBITDA | — | 337.7M | 329.1M | 219.5M | 201.0M |
| D&A | — | 46.0M | 48.2M | 44.6M | 38.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026